Now Is the Time for All Good Compounders to Come to the Aid of Their Profession: What You Do Right Now to Advance Compounding's Advocacy Priorities Can Help Assure Your Profession's Future

A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

LEARN MORE

Now Is the Time for All Good Compounders to Come to the Aid of Their Profession: What You Do Right Now to Advance Compounding's Advocacy Priorities Can Help Assure Your Profession's Future

Author(s): Brunner Scott

Issue: Jul/Aug 2019 - Volume 23, Number 4
View All Articles in Issue

Page(s): 294-296

Now Is the Time for All Good Compounders to Come to the Aid of Their Profession: What You Do Right Now to Advance Compounding's Advocacy Priorities Can Help Assure Your Profession's Future Page 1

Download in electronic PDF format for $65

Abstract:

Related Keywords: Scott Brunner, CAE, International Academy of Compounding Pharmacists, IACP, advocacy, U.S. Food and Drug Administration, regulation, lobbying, U.S. Congress, FDA oversight, H.R. 1959, Pharmacy Compounding Advisory Committee, PCAC, list of active pharmaceutical ingredients, APIs, Drug Quality and Security Act, DQSA, Memorandum of Understanding, MOU

Related Categories: LEGAL, PROFESSIONAL ISSUES

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
Now Is the Time for All Good Compounders to Come to the Aid of Their Profession: What You Do Right Now to Advance Compounding's Advocacy Priorities Can Help Assure Your Profession's Future Brunner Scott	Jul/Aug 2019 Pg. 294-296
The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Miller David G	May/Jun 2014 Pg. 208
The International Academy of Compounding Pharmacists Introduces a New President Rice Baylor	Mar/Apr 2017 Pg. 116-117
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Brunner Scott	Jul/Aug 2020 Pg. 296-297
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr	Nov/Dec 2015 Pg. 487-488
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Allen Loyd V Jr	Sep/Oct 2015 Pg. 389-390
Legislative/Regulatory Update: From the International Academy of Compounding Pharmacists: Appropriations McCrory Gary	Mar/Apr 2016 Pg. 95-96
U.S. Food and Drug Administration Requests for Input on HR 3204 Enactment: The Drug Quality and Security Act of 2013 Miller David G	Jan/Feb 2014 Pg. 35-36
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Yoch Doug	Mar/Apr 2017 Pg. 95-102
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr	Jul/Aug 2016 Pg. 351 View Sample

Particle Measuring Systems - USP <797> Environmental Monitoring Solutions